FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' Weltruza, the first once-monthly subcutaneous injectable olanzapine for adults with schizophrenia, eliminating the need for post-injection monitoring and improving outpatient treatment convenience. This approval is based on Phase 3 clinical trial data showing efficacy in symptom reduction and a safety profile consistent with oral olanzapine.

This Wire brief sits within Fusion42's coverage of Health, and 20 sources have reported it between 9 Oct 2026 and 13 Oct 2026.